

## Literaturverzeichnis

Hamburger Ärzteblatt 11 | 2018

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekeh.de](mailto:verlag@aekeh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

### S. 12 – 15: Tumormetastasierung – Molekularbiologische Forschung

Von Prof. Dr. Udo Schumacher, Christine Stürken, Barbara Schmalfeldt

1. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. *Cell*. 2011;147(2):275-92.
2. Samatov TR, Tonevitsky AG, Schumacher U. Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. *Mol Cancer*. 2013;12(1):107.
3. Köhler S, Ullrich S, Richter U, Schumacher U. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. *British journal of cancer*. 2010;102(3):602-9.
4. Bethge A, Schumacher U, Wree A, Wedemann G. Are metastases from metastases clinical relevant? Computer modelling of cancer spread in a case of hepatocellular carcinoma. *PloS one*. 2012;7(4):e35689.
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*. 1990;61(5):759-67.
6. Vogelstein B, Kinzler KW. The Path to Cancer –Three Strikes and You're Out. *The New England journal of medicine*. 2015;373(20):1895-8.
7. Lange T, Samatov TR, Tonevitsky AG, Schumacher U. Importance of altered glycoprotein-bound N- and O-glycans for epithelial-to-mesenchymal transition and adhesion of cancer cells. *Carbohydrate research*. 2014;389:39-45.
8. Faryammanesh R, Lange T, Magbanua E, Haas S, Meyer C, Wicklein D, et al. SDA, a DNA aptamer inhibiting E- and P-selectin mediated adhesion of cancer and leukemia cells, the first and pivotal step in transendothelial migration during metastasis formation. *PloS one*. 2014;9(4):e93173.
9. Gebauer F, Wicklein D, Stubke K, Nehmann N, Schmidt A, Salamon J, et al. Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp<sup>-/-</sup>/rag2<sup>-/-</sup> mice. *Gut*. 2013;62(5):741-50.
10. Haustein V, Schumacher U. A dynamic model for tumour growth and metastasis formation. *Journal of clinical bioinformatics*. 2012;2(1):11.
11. Samatov TR, Galatenko VV, Block A, Shkurnikov MY, Tonevitsky AG, Schumacher U. Novel biomarkers in cancer: The whole is greater than the sum of its parts. *Semin Cancer Biol*. 2017;45:50-7.

### S. 26 – 28: Colitis Ulcerosa – Behandlung nach der aktualisierten S3-Leitlinie

Von Dr. Dominik Reher, Dr. Carolin F. Manthey, PD Dr. Michael Bläker, Prof. Dr. Samuel Huber

1. T. Kucharzik, A. Dignass, R. Atreya, B. Bokemeyer, P. Esters, K. Herrlinger, K. Kannengiesser, P. Kienle, J. Langhorst, A. Lügering, S. Schreiber, A. Stallmach, J. Stein, A. Sturm, N. Teich und B. Siegmund. S3-Leitlinie - Colitis Ulcerosa. AWMF online, 2018.
2. M.S. Silverberg, J. Satsangi, T. Ahmad, I.D.R. Arnott, C.N. Bernstein, S.R. Brant, R. Caprilli, J.-F. Colombel, C. Gasche, K. Geboes, D.P. Jewell, A. Karban, E.V. Loftus jr., A.S. Pena, R.H. Riddell, D.B. Sachar, S. Schreiber, A.H. Steinhart, S.R. Targan, S. Vermeire und B.F. Warren. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. *Canadian Journal of Gastroenterology and Hepatology*, 19(Suppl A):5A–36A, 2005.

## Literaturverzeichnis

Hamburger Ärzteblatt 11|2018

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: [verlag@aekeh.de](mailto:verlag@aekeh.de)

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

3. J.A. Eaden, K.R. Abrams und J.F. Mayberry. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut*, 48(4): 526–535, 2001.
4. C.-H. R. Choi, M.D. Rutter, A. Askari, G.H. Lee, J. Warusavitarne, M. Moorghen, S. Thomas-Gibson, B.P. Saunders, T.A. Graham und A.L. Hart. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. *The American Journal of Gastroenterology*, 110(7):1022–1034, 2015.
5. V. Annese, M. Daperno, M.D. Rutter, A. Amiot, P. Bossuyt, J. East, M. Ferrante, M. Götz, K.H. Katsanos, R. Kießlich, I. Ordas, A. Repici, B. Rosa, S. Sebastian, T. Kucharzik und R. Eliakim on behalf on ECCO. European evidence based consensus for endoscopy in inflammatory bowel disease. *Journal of Crohn's and Colitis*, 7(12):982–1018, 2013.
6. P.D. Collins, C. Mpofu, A.J. Watson und J.M. Rhodes. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *The Cochrane Library Rev* 2006:CD000279, 2006.
7. M.W.M.D. Lutgens, B. Oldenburg, P.D. Siersema, A.A. van Bodegraven, G. Dijkstra, D.W. Hommes, D.J. de Jong, P.C.F. Stokkers, C.J. van der Woude und F.P. Vleggaar. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. *British Journal of Cancer*, 101(10):1671–1675, 2009.
8. F. Magro, P. Gionchetti, R. Eliakim, S. Ardizzone, A. Armuzzi, M. Barreiro-de Acosta, J. Burisch, K.B. Gecse, A.L. Hart, P. Hindryckx, C. Langner, J.K. Limdi, G. Pellino, E. Zagorowicz, T. Raine und M. Harbord for the European Crohn's and Colitis Organisation (ECCO). Third european evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *Journal of Crohn's and Colitis*, 11(6):649–670, 2017.
9. R.H. Riddell, H. Goldman, D.F. Ransohoff, H.D. Appelman, C.M. Fenoglio, R.C. Haggitt, C. Ahren, P. Correa, S.R. Hamilton und B.C. Morson. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Human Pathology*, 14(11):931–968, 1983.
10. L. Laine, T. Kaltenbach, A. Barkun, K.R. McQuaid, V. Subramanian, R. Soetikno, J.E. East, F.A. Farraye, B. Feagan, J. Ioannidis et al. Scenic international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastrointestinal Endoscopy*, 81(3):489–501, 2015.
11. T. Thomas, K.A. Abrams, R.J. Robinson und J.F. Mayberry. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. *Alimentary Pharmacology & Therapeutics*, 25(6):657–668, 2007.
12. M. Fumery, P.S. Dulai, S. Gupta, L.J. Prokop, S. Ramamoorthy, W.J. Sandborn und S. Singh. Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, 15(5):665–674, 2017.
13. G.C. Nguyen, C.N. Bernstein, A. Bitton, A.K. Chan, A.M. Griffiths, G.I. Leontiadis, W. Geerts, B. Bressler, J.D. Butzner, M. Carrier, N. Chande, J.K. Marshall, C. Williams und C. Keaton. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. *Gastroenterology*, 146(3):835–848, 2014.
14. D.A. Thorley-Lawson. EBV the prototypical human tumor virus—just how bad is it? *Journal of Allergy and Clinical Immunology*, 116(2):251–261, 2005.
15. M.P. Thompson und R. Kurzrock. Epstein-barr virus and cancer. *Clinical Cancer Research*, 10(3):803–821, 2004.
16. L. Beaugerie, N. Brousse, A.M. Bouvier, J.F. Colombel, M. Lemann, J. Cosnes, X. Hebuterne, A. Cortot, Y. Bouhnik, J.P. Gendre, T. Simon, M. Maynadie, O. Hermine, J. Faivre, und F. Carrat, for the CESAME study group. Lymphoproliferative disorders

## Literaturverzeichnis

Hamburger Ärzteblatt 11 | 2018

Seite 3

Weidestr. 122 b  
22083 Hamburg  
Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *The Lancet*, 374(9701):1617–1625, 2009.

17. W. Fries, M. Cottone und A. Cascio. Systematic review: macrophage activation syndrome in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, 37(11):1033–1045, 2013.
18. W.J. Sandborn, C. Su, B.E. Sands, G.R. D'Haens, S. Vermeire, S. Schreiber, S. Danese, B.G. Feagan, W. Reinisch, W. Niezychowski, G. Friedman, N. Lawendy et al. for the OCTAVE Induction 1, OCTAVE Induction 2 and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, 376(18): 1723–1736, 2017.

### S. 30 – 31: Fahrtauglichkeit – Rätselhafter Verkehrsunfall eines Arztes

*Von Prof. Dr. Klaus Püschel, Dr. Günther Thayssen, Maria Focken*

1. Focken M, Püschel K. Konsequenzen aus dem Arbeitskreis VI „Rätselhafte Verkehrsunfälle und strafprozessuale Aufklärungspflicht“ beim 52. Verkehrsgerichtstag in Goslar. *Blutalkohol* 2014; 51 (3): 148
2. Verkehrsmedizinische Kompetenz ist ein wesentliches Element der Patientenberatung. Deutscher Ärztetag, Düsseldorf 2014. Beschlussprotokoll S. 322. *Dtsch. Ärztebl.* 2014; 111 (25)
3. Von Renteln-Kruse W, Dapp K, Neumann L, Anders J, Profener F, Brieler P, Püschel K. Mobilität und Verkehrssicherheit im Alter DE GRUYTER 2017. Berlin-Boston
4. Klein HH, Sechtem U, Trappe HJ. Fahreignung im Straßenverkehr bei kardiovaskulären Erkrankungen. *Dtsch. Ärztebl.* 2017; 114 (41):692-702
5. Püschel K, Focken M. Noch einmal: Krankheit und Kraftverkehr- mehr Konsequenz gefordert (insbesondere auf Seiten der Ärzteschaft). *Blutalkohol* 2015; 52(1): 10-17